Refractory Childhood Hodgkin Lymphoma Clinical Trial
Official title:
Hodgkin Disease (HD) Banking Study
This laboratory study is collecting and storing samples of tissue and blood from young patients with Hodgkin's lymphoma. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help the study of cancer in the future.
OBJECTIVES:
I. Establish a biologic specimen repository (of tumor tissue, tissue arrays, lymphoblastoid
cell lines, host DNA, tumor and host RNA, serum, and plasma) and database linked to clinical
features and outcomes from well-characterized cohorts of children and young adults with
Hodgkin's lymphoma.
II. Provide specimens from diagnosis, early response evaluation, completion of chemotherapy
and radiotherapy, long-term follow up, and relapse to study prognostic factors for early
response, relapse, long-term outcomes, and identification of new biological targets for
therapy.
OUTLINE: This is a multicenter study.
Patients enrolled on Hodgkin's lymphoma (HL) therapeutic clinical trials undergo collection
of tumor tissue samples at baseline and at relapse or disease progression. Serum and
anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of
course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after
diagnosis, and at relapse or disease progression.
Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval
clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral
blood samples at relapse or disease progression.
Patients enrolled more than 1 year after completion of treatment undergo collection of tumor
specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00005803 -
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01008462 -
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Completed |
NCT01780662 -
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05857969 -
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
|
||
| Completed |
NCT03860376 -
Ex Vivo Drug Sensitivity Testing and Mutation Profiling
|
||
| Completed |
NCT00027820 -
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
|
Phase 1/Phase 2 |